New treatments for systemic lupus erythematosus
Novel Immunoregulatory Therapeutics for Systemic Lupus Erythematosus
This study is exploring new medications to help people with lupus, a condition that affects the immune system, by testing them in mice to see how well they work and if they are safe, with the hope of finding better treatments for patients like you.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Biotherapeutics, INC. NIH-funded |
| Lab location | 1 site (Blacksburg, United States) |
| Project ID | NIH-10654040 on NIH RePORTER |
What this research studies
This research focuses on developing novel immunoregulatory drugs aimed at treating systemic lupus erythematosus (SLE), an autoimmune disease affecting millions. The approach combines advanced computational modeling with experimental methods to evaluate the efficacy and safety of new therapeutic compounds. The research will involve testing these compounds in mouse models and assessing their effects on disease markers and kidney health. Patients may benefit from innovative treatments that could improve their condition and quality of life.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with systemic lupus erythematosus who may not be responding well to current treatments.
Not a fit: Patients with other autoimmune diseases or those not diagnosed with systemic lupus erythematosus may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted therapies for patients with systemic lupus erythematosus.
How similar studies have performed: Previous research has shown promising results with similar immunoregulatory approaches in treating autoimmune conditions, indicating potential for success in this area.
Where this research is happening
Blacksburg, United States
- Biotherapeutics, INC. — Blacksburg, United States (Active)
Researchers
- Principal investigator: Leber, Andrew — Biotherapeutics, INC.
- Study coordinator: Leber, Andrew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.